NCT05974046View on ClinicalTrials.gov

Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

July 21, 2023

Study Completion Date

July 21, 2023

Conditions
Opioid Use Disorder
Interventions
DRUG

[14C]IDV184001AN

\[14C\]-IDV184001AN 200 mg/\~100 µCi/ 15 g oral suspension

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors

Lead Sponsor

Indivior Inc.
All Listed Sponsors
lead

Indivior Inc.

INDUSTRY

NCT05974046 - Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants | Biotech Hunter | Biotech Hunter